Patents by Inventor Marc Abrams

Marc Abrams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250122500
    Abstract: Lipid-conjugated oligonucleotide are provided herein that inhibit or reduce expression of target genes. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with an RNAi trigger induced decrease in target gene expression.
    Type: Application
    Filed: May 3, 2024
    Publication date: April 17, 2025
    Inventors: Bob Dale Brown, Maire Jung, Travis Grim, Matthew Costales, Marc Abrams, Martin Lee Koser, Beata Kaminska, Jessica Lapierre
  • Patent number: 12252691
    Abstract: Oligonucleotides are provided herein that inhibit apolipoprotein(a) (LPA) expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with LPA expression.
    Type: Grant
    Filed: August 16, 2024
    Date of Patent: March 18, 2025
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob Dale Brown, Henryk T. Dudek, Marc Abrams, Wen Han, Anton Turanov
  • Publication number: 20240401053
    Abstract: Oligonucleotides are provided herein that inhibit apolipoprotein (a) (LPA) expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with LPA expression.
    Type: Application
    Filed: August 16, 2024
    Publication date: December 5, 2024
    Inventors: Bob Dale Brown, Henryk T. Dudek, Marc Abrams, Wen Han, Anton Turanov
  • Publication number: 20240401059
    Abstract: Oligonucleotides and compositions including the same are disclosed for inhibiting or reducing patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene expression. Methods of making and using the oligonucleotides also are disclosed, particularly uses relating to treating diseases, disorders and/or conditions associated with PNPLA3 expression.
    Type: Application
    Filed: August 2, 2024
    Publication date: December 5, 2024
    Inventors: Utsav Saxena, Henryk T. Dudek, Marc Abrams, Anton Turanov, Bob Dale Brown
  • Patent number: 12084662
    Abstract: Oligonucleotides and compositions including the same are disclosed for inhibiting or reducing patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene expression. Methods of making and using the oligonucleotides also are disclosed, particularly uses relating to treating diseases, disorders and/or conditions associated with PNPLA3 expression.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: September 10, 2024
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Utsav Saxena, Henryk T. Dudek, Marc Abrams, Anton Turanov, Bob Dale Brown
  • Publication number: 20230190753
    Abstract: Disclosed herein are methods for the treatment of cancer, comprising administering to a subject a ?-catenin nucleic acid inhibitor molecule and a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule. Also disclosed herein is a pharmaceutical composition comprising a therapeutically effective amount of a ?-catenin nucleic acid inhibitor molecule; a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule and at least one pharmaceutical carrier.
    Type: Application
    Filed: October 28, 2022
    Publication date: June 22, 2023
    Inventors: Marc Abrams, Shanthi Ganesh
  • Patent number: 11572559
    Abstract: Provided herein are methods and compositions for treating cancer, including cancer that is not responsive to immunotherapy. In one aspect, the methods of treatment comprise administering to the subject a therapeutically effective amount of a ?-catenin inhibitor and a therapeutically effective amount of an immunotherapeutic agent. Another aspect is directed to pharmaceutical compositions comprising a ?-catenin inhibitor for use in treating cancer, wherein the composition is administered in combination with an immunotherapeutic agent. Yet another aspect is directed to a method of potentiating the therapeutic effect of immunotherapy against a cancer using a ?-catenin inhibitor, such as a ?-catenin nucleic acid inhibitor molecule.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: February 7, 2023
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Shanthi Ganesh, Marc Abrams
  • Patent number: 11504374
    Abstract: Disclosed herein are methods for the treatment of cancer, comprising administering to a subject ?-catenin nucleic acid inhibitor molecule and a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule. Also disclosed herein is a pharmaceutical composition comprising a therapeutically effective amount of ?-catenin nucleic acid inhibitor molecule; a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule and at least one pharmaceutical carrier.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: November 22, 2022
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Marc Abrams, Shanthi Ganesh
  • Patent number: 11478501
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing HMGB1 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of HMGB1 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of HMGB1 expression may also be designed to include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat liver fibrosis and related conditions.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: October 25, 2022
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Marc Abrams, Girish Chopda, Jihye Park
  • Patent number: 11273173
    Abstract: This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: March 15, 2022
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Martin Koser, Marc Abrams
  • Patent number: 11052104
    Abstract: This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: July 6, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Martin Koser, Marc Abrams
  • Patent number: 11052105
    Abstract: This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: July 6, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Martin Koser, Marc Abrams
  • Publication number: 20210015820
    Abstract: Disclosed herein are methods for the treatment of cancer, comprising administering to a subject ?-catenin nucleic acid inhibitor molecule and a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule. Also disclosed herein is a pharmaceutical composition comprising a therapeutically effective amount of ?-catenin nucleic acid inhibitor molecule; a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule and at least one pharmaceutical carrier.
    Type: Application
    Filed: September 29, 2020
    Publication date: January 21, 2021
    Inventors: Marc Abrams, Shanthi Ganesh
  • Patent number: 10821112
    Abstract: Disclosed herein are methods for the treatment of cancer, comprising administering to a subject a ?-catenin nucleic acid inhibitor molecule and a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule. Also disclosed herein is a pharmaceutical composition comprising a therapeutically effective amount of a ?-catenin nucleic acid inhibitor molecule; a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule and at least one pharmaceutical carrier.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: November 3, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Marc Abrams, Shanthi Ganesh
  • Patent number: 10805157
    Abstract: A system and method supporting over-the-air programming of access device such as, for example, a mobile multimedia handset and a wireless personal digital assistant (PDA) via a broadband access gateway, is disclosed. The broadband access gateway may receive identifying information from the access device via a personal area network and/or a wireless local area network, and may transfer the identifying information to a wide area network or a third party content provider, via a broadband network. The broadband access gateway may enable the registration of the access device with the wide area network, and may receive firmware/software updates and/or provisioning parameters via the broadband network. The gateway may then transfer the firmware/software update and/or provisioning parameters to the access device via the personal area network and/or wireless local area network.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: October 13, 2020
    Assignee: AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED
    Inventors: Jeyhan Karaoguz, Marc Abrams, Nambirajan Seshadri
  • Patent number: 10799524
    Abstract: This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: October 13, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Martin Koser, Marc Abrams
  • Patent number: 10675295
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing HMGB1 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of HMGB1 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of HMGB1 expression may also be designed to include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat liver fibrosis and related conditions.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: June 9, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Marc Abrams, Girish Chopda, Jihye Park
  • Publication number: 20200171069
    Abstract: This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.
    Type: Application
    Filed: February 14, 2020
    Publication date: June 4, 2020
    Inventors: Martin Koser, Marc Abrams
  • Publication number: 20190070180
    Abstract: Disclosed herein are methods for the treatment of cancer, comprising administering to a subject a ?-catenin nucleic acid inhibitor molecule and a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule. Also disclosed herein is a pharmaceutical composition comprising a therapeutically effective amount of a ?-catenin nucleic acid inhibitor molecule; a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule and at least one pharmaceutical carrier.
    Type: Application
    Filed: March 15, 2017
    Publication date: March 7, 2019
    Inventors: Marc Abrams, Shanthi Ganesh
  • Publication number: 20190000870
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing HMGB1 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of HMGB1 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of HMGB1 expression may also be designed to include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat liver fibrosis and related conditions.
    Type: Application
    Filed: June 29, 2018
    Publication date: January 3, 2019
    Applicant: Dicerna Pharmaceuticals, Inc.
    Inventors: Marc Abrams, Girish Chopda, Jihye Park